FIGURE 2.

Administration of oroxylin A notably ameliorated both the CUMS-induced and CRS-induced behavioral symptoms in mice. (A) Two schematics respectively showing the timeline of the experimental procedures involving CUMS and CRS. (B) Mice subjected to CUMS were given daily administration of vehicle, paroxetine (20 mg/kg) or oroxylin A (2 and 5 mg/kg) during the last 2 weeks, and afterwards, behavioral tests were performed. Mice in the (CUMS + oroxylin A)-treated and (CUMS + paroxetine)-treated groups spent significantly less time being immobile than mice in the (CUMS + vehicle)-treated group in the FST and TST. Also, mice in the (CUMS + oroxylin A)-treated and (CUMS + paroxetine)-treated groups displayed notably higher sucrose preference than mice in the (CUMS + vehicle)-treated group. (C) Mice subjected to CRS were given daily administration of vehicle, paroxetine (20 mg/kg) or oroxylin A (2 and 5 mg/kg) during the last 2 weeks, and afterwards, behavioral tests were performed. Mice in the (CRS + oroxylin A)-treated and (CRS + paroxetine)-treated groups had significantly less immobility than mice in the (CRS + vehicle)-treated group in the FST and TST. Also, mice in the (CRS + oroxylin A)-treated and (CRS + paroxetine)-treated groups exhibited evidently higher sucrose preference than mice in the (CRS + vehicle)-treated group. All data are displayed as means ± S.E.M. (n = 12); ^** p < 0.01 vs. Vehicle; ^## p < 0.01 vs. (CUMS + Vehicle) or (CRS + Vehicle). The statistical comparisons were achieved by (Two-way ANOVA + Bonferroni’s test).